Avidity Biosciences, Inc. (RNA) Net Margin (2019 - 2025)
Avidity Biosciences' Net Margin history spans 7 years, with the latest figure at 27514.42% for Q4 2025.
- For Q4 2025, Net Margin fell 2406814.0% year-over-year to 27514.42%; the TTM value through Dec 2025 reached 3640.03%, down 68459.0%, while the annual FY2025 figure was 3640.03%, 68459.0% down from the prior year.
- Net Margin reached 27514.42% in Q4 2025 per RNA's latest filing, down from 1395.29% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 881.69% in Q1 2021 to a low of 27514.42% in Q4 2025.
- Average Net Margin over 5 years is 3722.96%, with a median of 2050.92% recorded in 2021.
- The largest YoY upside for Net Margin was 203648bps in 2025 against a maximum downside of -2406814bps in 2025.
- A 5-year view of Net Margin shows it stood at 2078.4% in 2021, then grew by 12bps to 1822.07% in 2022, then plummeted by -51bps to 2751.39% in 2023, then fell by -25bps to 3446.28% in 2024, then tumbled by -698bps to 27514.42% in 2025.
- Per Business Quant, the three most recent readings for RNA's Net Margin are 27514.42% (Q4 2025), 1395.29% (Q3 2025), and 4072.37% (Q2 2025).